{"filing":{"accession_number":"0001601485-26-000055","cik":"0001601485","ticker":"ELTX","company_name":"Elicio Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"eltx-20260813.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1601485/000160148526000055/eltx-20260813.htm"},"events":[{"id":27621,"run_id":25186,"accession_number":"0001601485-26-000055","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard quarterly earnings release for Q2 2026 filed under Item 2.02. The press release (Exhibit 99.1) discloses financial results including R\u0026D expense ($6.8M), G\u0026A expense ($3.6M), net loss ($8.2M), net loss per share ($0.43), and cash position ($23.5M as of June 30, 2026), along with corporate updates on clinical trials and financing activities. The disclosure is material as it provides investors with the company's financial performance and operational progress for the quarter.","company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29212,"accession_number":"0001601485-26-000055","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for Q2 2026 filed under Item 2.02. The press release (Exhibit 99.1) discloses financial results including R\u0026D expense ($6.8M), G\u0026A expense ($3.6M), net loss ($8.2M), net loss per share ($0.43), and cash position ($23.5M as of June 30, 2026), along with corporate updates on clinical trials and financing activities. The disclosure is material as it provides investors with the company's financial performance and operational progress for the quarter.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:04:08.544413+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29212,"accession_number":"0001601485-26-000055","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for Q2 2026 filed under Item 2.02. The press release (Exhibit 99.1) discloses financial results including R\u0026D expense ($6.8M), G\u0026A expense ($3.6M), net loss ($8.2M), net loss per share ($0.43), and cash position ($23.5M as of June 30, 2026), along with corporate updates on clinical trials and financing activities. The disclosure is material as it provides investors with the company's financial performance and operational progress for the quarter.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:04:08.544413+00:00","company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","filing_date":"2026-08-13"}]}